Drug Trial Radar · NCT06452433
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Last checked: Nov 20, 2026Latest source record: Jun 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
91
Planned (sponsor's estimate)
Start
Jun 1, 2024
Primary completion
Dec 12, 2027
Study completion Feb 2, 2028
Sponsor
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the efficacy and safety of gumarontinib combined with third-generation EGFR-TKI in the treatment of locally advanced or metastatic NSCLC with MET amplification after first-line EGFR-TKI failure, without limiting the type of third-generation EGFR-TKI. The study was divided into 2 cohorts: Cohort 1 included patients with MET amplification after third-generation EGFR-TKI first-line therapy resistance, and cohort 2 included patients with MET amplification after first-generation EGFR-TKI first-line therapy resistance.
Conditions
- Non-small Cell Lung Cancer
Interventions
gumarontinibDrug
300 mg , qd ,po, expect 6 months.
third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)Drug
According to the actual situation of patients. Take as recommended, expect 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: From initial medication to the date of first documented progression or end of medication. Assessed up to 6 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.